目的 探讨金水宝胶囊联合布地奈德福莫特罗粉吸入剂治疗慢性阻塞性肺疾病稳定期的临床疗效。方法 选取2017年3月-2018年8月在陕西中医药大学第一附属医院就诊的94例慢性阻塞性肺疾病稳定期患者作为研究对象，按照随机数字表法分为对照组和治疗组，每组各47例。对照组雾化吸入布地奈德福莫特罗粉吸入剂，1吸/次，2次/d。治疗组在对照组基础上口服金水宝胶囊，3粒/次，3次/d。两组患者连续治疗3个月。观察两组的临床疗效，比较两组的肺功能和免疫功能。结果 治疗后，对照组和治疗组的总有效率分别为78.72%、93.62%，两组比较差异有统计学意义（P<0.05）。治疗后，两组的FEV1（第一秒用力呼气容积）、FEV1/FVC（用力肺活量）、第1秒用力呼气容积占预计值百分比（FEV1% pred）、功能残气量（FRC）均明显升高，同组治疗前后差异有统计学意义（P<0.05）；治疗后治疗组的FEV1、FEV1/FVC、FEV1% pred、FRC明显高于对照组，差异有统计学意义（P<0.05）。治疗后，两组的CD4⁺、CD4⁺/CD8⁺均明显升高，辅助性T细胞17（Th17细胞）、Th17细胞/调节性T细胞（Treg细胞）均明显降低，同组治疗前后比较差异有统计学意义（P<0.05）；治疗后治疗组的CD4⁺、CD4⁺/CD8⁺高于对照组，Th17细胞、Th17细胞/Treg细胞低于对照组，差异有统计学意义（P<0.05）。结论 金水宝胶囊联合布地奈德福莫特罗粉吸入剂治疗慢性阻塞性肺疾病稳定期具有较好的临床疗效，可改善肺功能，调节免疫功能，具有一定临床推广应用价值。

Objective To investigate the clinical effect of Jinshuibao Capsules combined with Budesonide and Formoterol Fumarate Powder for inhalation in treatment of stable chronic obstructive pulmonary disease. Methods Patients (94 cases) with stable chronic obstructive pulmonary disease in the First Affiliated Hospital of Shaanxi University of Traditional Chinese Medicine from March 2017 to August 2018 were randomly divided into control and treatment groups, and each group had 47 cases. Patients in the control group were atomization inhalation administered with Budesonide and Formoterol Fumarate Powder for inhalation, 1 suction/time, twice daily. Patients in the treatment group were po administered with Jinshuibao Capsules on the basis of the control group, 3 grains/time, three times daily. Patients in two groups were treated for 3 months. After treatment, the clinical efficacies were evaluated, and pulmonary function and immune function in two groups were compared. Results After treatment, the clinical efficacies in the control and treatment groups were 78.72% and 93.62%, respectively, and there was difference between two groups (P<0.05). After treatment, FEV1, FEV1/FVC, FEV1% pred, and FRC in two groups were significantly increased, and the difference was statistically significant in the same group (P<0.05). And the pulmonary function indexes in the treatment group were significantly higher than those in the control group, with significant difference between two groups (P<0.05). After treatment, CD4⁺ and CD4⁺/CD8⁺ in two groups were significantly increased, but Th17 cell, Th17 cell/Treg cell in two groups were significantly decreased, and the difference was statistically significant in the same group (P<0.05). And the immune function indexes in the treatment group were significantly better than those in the control group, with significant difference between two groups (P<0.05). Conclusion Jinshuibao Capsules combined with Budesonide and Formoterol Fumarate Powder for inhalation has clinical effect in treatment of stable chronic obstructive pulmonary disease, can improve pulmonary function and regulate immune function, which has a certain clinical application value.

R974